BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Orticumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Orticumab\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06927739-1122@assetmemo.bio
DTSTAMP:20261121T005807Z
DTSTART;VALUE=DATE:20270208
DTEND;VALUE=DATE:20270209
SUMMARY:Orticumab: Phase 2 readout est. (NCT06927739)
DESCRIPTION:Orticumab\, phase 2\, Atherosclerotic Cardiovascular Disease.\n
 Study: Focused Orticumab Research for Treating Inflammation in Coronary Ar
 teries\nEstimated primary completion: 8 February 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/orticumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06927739
URL:https://assetmemo.bio/drug/orticumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
